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Introduction: Cell-based therapies (CBTs) have been shown to confer regenerative capacity in various pathologies. The production of such treatments requires a range of business models. These business models either align with or disrupt the current clinical pathway and therefore it is imperative to understand the impact at the clinical interface and to design manufacture and supply networks in a way that makes adoption as simple as possible. The present study explores the delivery of cell therapy within several NHS Trust hospitals. CBTs are manufactured under a controlled GMP background, requiring specialist equipment and expertise. This often presents unexpected costs and operational procedures that are unfamiliar to the typical clinical environment.
Methods:
This project takes a focus on the flow of information and activities from 'needle-to-needle' for a culture-expanded autologous chondrocyte implantation (ACI) product in a Phase-II clinical trial at a local NHS Trust. A framework has been identified based on conceptual modelling under the IDEF0 standard to understand fundamental unit operations. Activity-based costing has been applied to value-adding activities to assess direct and indirect costs of manufacture.
A sensitivity analysis has explored how manufacturing parameters, facility overheads and the operational model has impacted upon the cost drivers. Comparison of CBT manufacture at further NHS sites has been explored to understand current practices and the feasibility of change to allow for increased capacity within the constraints of existing infrastructure. Semi-structured interviews have been undertaken with key players through the innovation, adoption and implementation process. Consensus statements have been developed through a two-round Delphi method in order to provide guidance for prospective CBT manufacturers and the NHS.
